Contact

PPCE Selects eClinicalOS™ for Rheumatoid Arthritis Trial eClinicalOS, arthritis, PPCE, eClinical, rheumatoid arthritis Study for PPCE is first in India for Merge eClinical

PPCE Selects eClinicalOS™ for Rheumatoid Arthritis Trial

Study for PPCE is first in India for Merge eClinical

PPCE selected the eClinicalOS data management platform from Merge eClinical for a rheumatoid arthritis study for a Singapore-based pharmaceuticals company. While the number of eClinicalOS-based trials outside the U.S. has grown steadily since its launch in 2012, this study represents the first time the platform has been used to administer a trial in India.

“eClinicalOS is an excellent tool with a range of optional modules such as Translation, e-PRO, Randomization, DICOM Imaging, Endpoint Adjudication and customizable CTMS integrated into a comprehensive, user-friendly platform,” said Amit Kumar Yadav, business development manager at PPCE. “The ability to combine the power of an end-to-end study management platform with the scalability offered through the pay-as-you-go option made our decision to go with eClinicalOS an easy one.”

Mr. Yadav also noted the eClinicalOS platform’s design allowed the PPCE team to build and launch the study in only seven weeks. “Quite frankly, we were surprised at how quickly we could design the study and have it ready to go live, considering that this was the first time we were using the platform.”

“Our goal is for eClinicalOS to be the standard data management platform no matter a study’s size, complexity or location. We are tremendously excited to expand our global footprint of more than 80 countries to include a critical market such as India,” said Merge eClinical President Zaher El-Assi.

Mr. El-Assi also noted that PPCE and its client were specific in the functions and features needed from a data management system. “They wanted a fully integrated software platform that was intuitive, didn’t require steep upfront costs and could provide real-time access to clinical data for quick decision-making. That right there is a perfect description of eClinicalOS,” he said.

According to Khushnoor Dastoor, executive director and head of quality assurance at PPCE, more stringent regulations coupled with increased cost pressure are pushing the clinical research market to adopt technology to an even greater extent than in recent years. “Clinical research professionals place great faith in systems that are strong on ‘fool proofing.’ To this end, we want platforms that reduce the need for manual entry and disallow illogical data from being entered, thereby reducing errors through automation. eClinicalOS is an excellent example of that technology,” she said.

About Merge eClinical
 
Merge eClinical is a division of Merge Healthcare, Inc. (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare. eClinicalOS, the company’s flagship product, is a single, scalable cloud-based platform researchers can configure to suit a study’s precise needs. From monitoring inventory and managing randomization to endpoint adjudication and archiving results, users pay only for the options they use. Studies built within eClinicalOS can launch in as few as 10 days, and the average deployment time from project initiation is 40 days. More information is available at www.eclinicalos.com.
 
About Merge
 
Merge is a leading provider of innovative enterprise imaging, interoperability and clinical systems that seek to advance healthcare. Merge’s enterprise and cloud-based technologies for image intensive specialties provide access to any image, anywhere, any time. Merge also provides clinical trials software with end-to-end study support in a single platform and other intelligent health data and analytics solutions. With solutions that have been used by providers for more than 25 years, Merge is helping to reduce costs, improve efficiencies and enhance the quality of healthcare worldwide. For more information, visit merge.com and follow us at @MergeHealthcare.
 
About PPCE
 
PPCE was founded in 1997 with a vision to add value to industry by encouraging “zero-defect” and the prevention of problems arising out of poor quality. 
PPCE offers cost effective clinical data management, bio-statistics and medical writing services for paper based, electronic and hybrid studies. Solutions used are validated, world renowned and regulatory compliant across the globe. Fully validated, 21 CFR Part 11 compliant platforms enable PPCE to offer its clients world-class tools for high-quality data.
We are a company focused on quality and on-time delivery for our clients. PPCE’s 16 years of experience certifying companies for quality management means that critical aspects of quality, such as integrity of data, confidentiality and customer orientation, form part of the organizational culture. As a result of this culture, we enjoy a high level of customer satisfaction and long-term relationships with our clients. For more information, visit www.ppceworld.com.

Cautionary Notice Regarding Forward-Looking Statements
 
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.

Contact:
Steven Tolle
Chief Strategy Officer
312.946.2503
steven.tolle@merge.com

 Download this press release >>

© 2017 IBM Watson Health. All Rights Reserved. Privacy | Terms | Email Signup | Sitemap